Aptorum Group Ltd Class A APM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.17
- Day Range
- $1.11–1.21
- 52-Week Range
- $0.65–4.47
- Bid/Ask
- $1.13 / $1.15
- Shares Outstanding
- 8.14M
- Market Cap
- $9.28M
- Volume/Avg
- 496,189 / 121,848
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.aptorumgroup.com
Valuation
|
Metric
|
APM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.41 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APM
Financial Strength
|
Metric
|
APM
|
|---|---|
Quick Ratio | 0.75 |
Current Ratio | 0.78 |
Interest Coverage | −13.38 |
Quick Ratio
APM
Profitability
|
Metric
|
APM
|
|---|---|
Return on Assets (Normalized) | −10.85% |
Return on Equity (Normalized) | −8.51% |
Return on Invested Capital (Normalized) | −10.99% |
Return on Assets
APM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Cjttpcgs | Czqpc | $112B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Whpdnxgk | Dtgsw | $64B | |||
| argenx SE ADR
ARGX
| Zmnsjwmvf | Dvyg | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lcmjwyh | Wmlbpy | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Sygvvfsbg | Dkzylnb | $24B | |||
| BioNTech SE ADR
BNTX
| Zwbdtdm | Wnsz | $22B | |||
| Incyte Corp
INCY
| Xkpcbpqlc | Ymyf | $20B | |||
| Moderna Inc
MRNA
| Rywmhxx | Ywkl | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Wlzwqjyrl | Dkwpv | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Vmcgfwbg | Tspj | $13B |
United States